FDA accepts Spectrum's Zevalin response

The FDA has accepted for review Spectrum Pharmaceuticals' response on the experimental cancer drug Zevalin as a Class 1 submission, setting a deadline of September 7 for its final decision. That's the kind of news that investors were looking for. Spectrum's stock surged on the news. The agency had asked for more data from Spectrum, which is looking to gain approval to use Zevalin to treat non-Hodgkins lymphoma. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.